Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

Gupta, SK; Berhe, M; Crofoot, G; Benson, P; Ramgopal, M; Sims, J; McDonald, C; Ruane, P; Sanchez, WE; Scribner, A; Liu, SY; VanderVeen, LA; Dvory-Sobol, H; Rhee, MS; Baeten, JM; Koenig, E

Gupta, SK (通讯作者)，Indiana Univ Sch Med, Indianapolis, IN 46202 USA.

LANCET HIV, 2023; 10 (1): E15

Abstract

Background Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索